Evofem Biosciences Inc Quick Ratio (EVFM) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Evofem Biosciences Inc   (EVFM)

Evofem Biosciences Inc 's Quick Ratio

EVFM's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.01 below Evofem Biosciences Inc average.

Within Major Pharmaceutical Preparations industry 448 other companies have achieved higher Quick Ratio than Evofem Biosciences Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 4259, from total ranking in the first quarter 2026 at 5413.

Explain Quick Ratio?
How much Cash & cash equivalents EVFM´s has?
What are EVFM´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EVFM Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 19.92 % 11.15 % 28.17 % 2.49 % 0.98 %
Y / Y Cash & cash equivalent Change - 976.47 % - - -
Quick Ratio MRQ 0.01 0.03 0.01 - -
EVFM's Total Ranking # 4259 # 5413 # # # 5496
Seq. Current Liabilities Change 12.52 % -7.15 % 8.48 % 5.81 % 4.29 %
Seq. Cash & cash equivalent Change -69.99 % 311.59 % - - -



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 449
Healthcare Sector # 913
Overall Market # 4408


Quick Ratio Statistics
High Average Low
39.77 3.28 0
(Dec 31 2014)   (Mar 31 2025)




Financial Statements
Evofem Biosciences Inc 's Current Liabilities $ 89 Millions Visit EVFM's Balance sheet
Evofem Biosciences Inc 's Cash & cash equivalent $ 1 Millions Visit EVFM's Balance sheet
Source of EVFM's Sales Visit EVFM's Sales by Geography


Cumulative Evofem Biosciences Inc 's Quick Ratio

EVFM's Quick Ratio for the trailling 12 Months

EVFM Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 15.03 % 10.18 % 6.17 % -2.38 % 1.73 %
Y / Y Cash & cash equivalent TTM Growth 1561.09 % 1238.01 % - - -
Quick Ratio TTM 0.01 0.01 0 0 0
Total Ranking TTM # 4010 # 4763 # 3698 # 3752 # 3815
Seq. Current Liabilities TTM Growth 4.66 % 2.57 % 6.45 % 0.66 % 0.25 %
Seq. Cash & cash equivalent TTM Growth 24.15 % 270.09 % 261.54 % 0 % 0 %

Quick ratio ranking by company, industry and sector >> Back to EVFM Financial Strength Comparisons >> Go to Compare EVFM Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the increase in Current Liabilities in the Q2 2026 to $88.62 millions, cumulative Quick Ratio remained unchanged at 0.01 below the Evofem Biosciences Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 445 other companies have achieved higher Quick Ratio than Evofem Biosciences Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 4144.

Explain Quick Ratio?
How much Cash & cash equivalents EVFM´s has?
What are EVFM´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 446
Healthcare Sector # 914
Within the Market # 4259


trailing twelve months Quick Ratio Statistics
High Average Low
7.16 1.12 0
(Dec 31 2015)   (Sep 30 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Northwest Biotherapeutics Inc  0.01 $ 0.595  Millions$ 42.982  Millions
Oncotelic Therapeutics Inc   0.01 $ 0.186  Millions$ 17.907  Millions
Os Therapies Incorporated  0.01 $ 0.205  Millions$ 20.653  Millions
The Greater Cannabis Company Inc   0.01 $ 0.000  Millions$ 0.012  Millions
Chemocentryx Inc.  0.01 $ 1.253  Millions$ 139.868  Millions
NIKA PHARMACEUTICALS, INC  0.01 $ 0.003  Millions$ 0.341  Millions
Evofem Biosciences Inc   0.01 $ 0.714  Millions$ 88.615  Millions
Rain Enhancement Technologies Holdco Inc   0.01 $ 0.071  Millions$ 13.574  Millions
IMPACT BIOMEDICAL INC. 0.00 $ 0.010  Millions$ 2.045  Millions
Semnur Pharmaceuticals Inc 0.00 $ 0.039  Millions$ 10.672  Millions
Cnbx Pharmaceuticals Inc 0.00 $ 0.010  Millions$ 2.673  Millions
Accustem Sciences Inc 0.00 $ 0.013  Millions$ 5.724  Millions

Date modified: 2026-09-26T07:01:42+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.